[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-bmi--25\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-bmi--25":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,79,117,142,165,192,221,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644284","fasting-exercise-and-diet-to-activate-autophagy-in-depression-100644284",false,"NCT07664540","Fasting, Exercise, and Diet to Activate Autophagy in Depression","Targeting Autophagy in Depression: Fasting, Exercise, Diet","AutoFast","Inclusion Criteria:\n\n* age: 18-40 years\n* BMI: between 18.5 and 24.9 kg\u002Fm2 (SG1\u002F2) or BMI between 25.0 and 39.9 kg\u002Fm2 (SG3\u002F4)\n* ability to understand the study procedure and give consent\n* Written informed consent\n* SG1 women: any fitness level\n* SG2 men: VO2max \\\u003C 45 ml\u002Fkg\u002FKG29,30\n* Available to conduct CPET on menstrual cycle days 1-5 (SG1\u002F3)\n* No infection with HIV or Hepatitis B\u002FC\n\nExclusion Criteria:\n\n* No infectious illness for at least two weeks prior to the test\n* No vitamin supplementation during the week prior to the performance test\n* SG3 and SG4: More than 1 hour moderate exercise per week\n* No use of hormonal contraceptives in the last 6 months before the onset of the study (SG1\u002F3)\n* a clinically diagnosed menstrual disorder (e.g., polycystic ovarian syndrome or amenorrhea) (SG1\u002F3)\n* having given birth within the 12 months before inclusion in the study (SG1\u002F3)\n* pregnancy or breastfeeding (SG1\u002F3)\n* premenstrual dysphoric disorder (PMDD) (SG1\u002F3)\n* history of epileptic seizure\n* history of depression\n* history of manic or psychotic episode\n* existing\u002Fcurrent eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years\n* inability to communicate adequately in speech\n* inability to follow instructions\n* regular use of medication other than thyroxine\n* alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day on average for women and 24 g of pure alcohol per day for men\n* vegan diet\n* daily nicotine consumption\n* currently or history of (regular) consumption of illegal drugs within the last year\n* known diseases of the cardiovascular system\n* arterial hypertension above 160\u002F90 mmHg at rest\n* known pulmonary diseases\n* arthritis and rheumatic diseases and conditions\n* hematologic diseases\n* bronchial asthma\n* surgery less than 4-6 months ago\n* orthopedic or other diseases (e.g. neurological) that preclude maximum load on the bicycle ergometer\n* anemia (\\\u003C12.0 g\u002Fdl for women and \\\u003C14.0 g\u002Fdl for men)",true,"ALL","18 Years","40 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","Depression is a common mental health condition that affects millions of people worldwide and is a leading cause of disability. Although current treatments can be effective, many patients do not fully recover or experience long-term improvement. This study aims to better understand how lifestyle factors such as physical activity and diet-related processes may influence biological mechanisms that could be linked to depression.\n\nThe study focuses on a natural cellular process called autophagy, which helps cells remove damaged components and maintain healthy function. Autophagy is influenced by energy availability in the body and may be affected by behaviors such as physical exercise and caloric restriction. Early evidence suggests that changes in autophagy may also be linked to mood regulation and depression, but this relationship is not yet well understood in humans.\n\nIn this exploratory study, we will investigate how physical activity influences autophagy and related metabolic and molecular processes in healthy adults. We will also examine whether these effects differ between individuals with different body weight and fitness levels, and between women and men.\n\nA total of approximately 120 healthy adults aged 18 to 40 years will participate. Participants will be divided into four groups based on sex and body weight (normal weight or overweight). Each participant will attend study visits at the University Hospital Zurich and perform a standardized cycling exercise test under medical supervision.\n\nDuring the exercise test, participants will perform a graded cycling protocol that gradually increases in intensity until exhaustion. We will collect small blood samples from a vein and from a fingertip at several time points before, during, and after exercise. Saliva samples will also be collected to measure stress-related hormones. Additional measurements include heart rate, breathing parameters, oxygen consumption, and physical performance.\n\nBlood and saliva samples will be analyzed using advanced laboratory techniques to study changes in metabolism, immune signaling, hormones, gene activity, and markers related to autophagy. These analyses will help identify biological pathways that are activated by exercise and may be relevant to brain health and depression.\n\nParticipants will undergo medical screening before inclusion to ensure safety. Individuals with certain medical conditions or factors that could interfere with the study results will not be included. Participation is voluntary, and participants may withdraw at any time without consequences.\n\nThe study involves minimal risks associated with blood sampling and intense physical exercise, which will be performed under close medical supervision. The expected benefit is improved scientific understanding of how lifestyle-related biological processes may be linked to mental health, which could support the development of new preventive or therapeutic strategies for depression in the future.",[29,30],"Depression - Major Depressive Disorder","Overweight (BMI > 25)",[32,33,34,35,36,37,38,39],"autophagy","multi-omics","depression","steroid hormones","autophagy flux","performance testing","metabolomics","proteomics","NOT_YET_RECRUITING","2026-06-17",{"date":43,"type":44},"2026-06-24","ACTUAL",{"date":46,"type":23},"2026-09-11",{"date":48,"type":23},"2029-09-30",{"name":50,"class":51},"University of Zurich","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100636487","assess-the-effects-of-replacing-foods-high-in-refined-carbohydrates-with-avocado-on-biomarkers-of-inflammation-100636487","NCT07566325","Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.","Effects of Avocado Consumption on Inflammation and Insulin Sensitivity in Adults With Elevated High Sensitivity-C-reactive Protein (Hs-CRP): A Randomized, Controlled Crossover Trial","Inclusion Criteria:\n\n1. Male or female 21 - 74 years of age, inclusive;\n2. Baseline hs-CRP ≥2 to \\\u003C10 mg\u002FL;\n3. Central adiposity (waist circumference ≥35 inches in women and ≥40 inches in men);\n4. Body mass index 25.0 to 39.9 kg\u002Fm2;\n5. Normally active and judged by the Investigator to be in generally good health, based on medical history and screening measurements;\n6. Willing to consume daily study foods during each diet condition;\n7. Willing to maintain his\u002Fher regular physical activity pattern throughout the study period;\n8. Willing to follow test day instructions (refrain from consumption of alcoholic beverages and participation in vigorous physical activity for 24 hours and tobacco and caffeine for 1 hour prior to each test visit);\n9. No plans to change smoking, vaping, or other nicotine use habits during the study period; and\n10. Premenopausal women that are not using hormonal contraceptives must have a history of regular menstrual cycles (21-35 days per cycle) for at least 3 months prior to visit 1;\n11. Understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures.\n\nExclusion Criteria:\n\n1. Calculated energy needs of \\\u003C1800 kcal\u002Fd per the Mifflin-St. Jeor Equation, with an adjustment for energy expended in physical activity;\n2. Known metabolic disease (e.g., type 1 or type 2 diabetes, metabolic dysfunction-associated steatohepatitis, etc.);\n3. Laboratory test result(s) of clinical significance based on the judgment of the Principal Investigator or qualified designee, including fasting glucose ≥126 mg\u002FdL;\n4. Positive urine test for illicit drugs at visit 1;\n5. Clinical atherosclerotic disease;\n6. History or presence of clinically significant gastrointestinal, endocrine, renal, hepatic, hematologic, immunologic, dermatologic, pulmonary, pancreatic, neurologic, psychiatric, inflammatory or biliary disorder that, in the opinion of the Investigator, could interfere with the interpretation of the study results;\n7. History of cancer in the prior 2 years, except for non- melanoma skin cancer or carcinoma in situ of the cervix;\n8. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and\u002For diastolic blood pressure ≥100 mm Hg) at screening;\n9. Unstable use (defined as initiation or change in dose) of anti-hypertensive medication within 4 weeks of visit 1;\n10. Unstable use (defined as initiation or change in dose) of thyroid hormone replacement medication within 12 weeks of visit 1;\n11. Use of beta-adrenergic blockers and\u002For high-dose (\\>25 mg\u002Fd) thiazide diuretics within 4 weeks of visit 1;\n12. Use of diabetes medications including glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonists, alpha-glucosidase inhibitors, biguanides and biguanide combinations, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides and sulfonylureas and combination sulfonylureas within 4 weeks of visit 1;\n13. Unstable use (defined as initiation or change in dose, agent, or regimen) of statins within 4 weeks of visit 1;\n14. Use of lipid-altering drugs other than statins including, but not limited to bile acid sequestrants, cholesterol absorption inhibitors, or fibrates within 4 weeks of visit 1;\n15. Use of any prescription medication with known effects on inflammation (e.g., colchicine, systemic corticosteroids) within 4 weeks of visit 1;\n16. Frequent use (≥4 doses\u002Fweek) of non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of visit 2;\n17. Use of weight-loss drugs (including over-the-counter medications and\u002For supplements) or participation in a structured weight loss program within 4 weeks prior to visit 1;\n18. Unstable use (initiation or change in dose) within 4 weeks of visit 1 of sex hormones. Multiphasic hormonal contraceptives in which the amount of sex hormone in the active pill varies by week (i.e., biphasic, triphasic, quadriphasic) are considered unstable doses of sex hormones and are exclusionary;\n19. History of bariatric surgery or plans to have any surgery during the study;\n20. History of any major trauma or major surgical event within 2 months of visit 1;\n21. Use of herbs or dietary supplements that may affect lipid metabolism, including but not limited to omega-3 fatty acid supplements with \\>500 mg of eicosapentaenoic acid (EPA) and\u002For docosahexaenoic acid (DHA), niacin (or its analogs) at doses \\>200 mg\u002Fd, sterol\u002Fstanol products, dietary fiber supplements, red rice yeast supplements, garlic supplements, and soy isoflavone supplements within 2 weeks of visit 2;\n22. Use of herbs and dietary supplements that may affect carbohydrate metabolism, including chromium picolinate, ginseng, cinnamon (as a supplement) and starch blockers within 2 weeks of visit 2;\n23. Recent weight change of ±4.5 kg (\\~10 lbs.) within 3 months prior to visit 1;\n24. Has signs and symptoms of an active infection of clinical significance or has taken antibiotics within 5 days prior to any visit (washout is permitted by re-scheduling of the clinic visit);\n25. Extreme dietary habits (e.g., vegan, very low carbohydrate);\n26. History of an eating disorder (e.g., anorexia, bulimia nervosa, or binge eating) either diagnosed by a health professional or self-reported;\n27. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period;\n28. Known allergy, sensitivity, or intolerance to any components of the study foods;\n29. Exposed to any non-registered drug product within 4 weeks of visit 1;\n30. Currently participating in another research study;\n31. Use of hemp\u002Fmarijuana products within 12 months of visit 1. Occasional use (e.g., once or twice a month) within 12 months of visit 1 is allowed but requires at least a 14-day washout prior to visit 2 and the participant must be willing to refrain from use during the study;\n32. Current or recent history (past 12 months of screening) or strong potential for illicit drug or alcohol abuse. Alcohol abuse will be defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor); and\n33. Condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.","21 Years","74 Years",{"count":63,"type":23},38,[26],"The objective of this trial is to assess the effects of replacing foods high in refined carbohydrates, particularly added sugars, with avocado (isocaloric substitution) on biomarkers of inflammation and insulin sensitivity in adults with elevated hs-CRP and central adiposity. Eligible participants will complete two 4-week interventions (1 avocado\u002Fd and control) separated by a 2-week washout phase. Participants will complete a total of 7 clinic visits including one screening visit (visit 1, -7 days), one baseline visit (visit 2, day 0), two visits during each 4-week diet condition (visit 3 \\& 6 on day 21 and visits 4 \\& 7 on day 28), and one visit at the conclusion of the washout phase\u002Fstart of the second condition (visit 5, day 0).",[30,67,68],"Obesity (BMI>30)","Hs-CRP","2026-05-04",{"date":71,"type":44},"2026-05-08",{"date":73,"type":23},"2026-05-11",{"date":75,"type":23},"2026-12",{"name":77,"class":51},"Midwest Center for Metabolic and Cardiovascular Research",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":52},"100635534","sustainable-and-inclusive-use-of-alternative-proteins-in-mediterranean-supply-chains-cipromed-100635534","NCT07553936","Sustainable and Inclusive Use of Alternative Proteins in Mediterranean Supply Chains (CIPROMED)","Circular and Inclusive Use of Alternative Proteins in Mediterranean Supply Chains (CIPROMED)","CIPROMED","Inclusion Criteria:\n\n* Providing signed informed consent,\n* Being between 18 and 65 years of age,\n* Having a body mass index (BMI) within the normal range, defined as between 18.5 and 24.9 kg\u002Fm² or Having a body mass index (BMI) between 25.0 and 34.9 kg\u002Fm², inclusive, corresponding to the overweight category or, at most, class I obesity.\n\nExclusion Criteria:\n\n* Positive and documented history of allergy to legumes, insects, microalgae, shellfish, mollusks, crustaceans, snails, insect venom, house dust mites, or any component (ingredient or additive) present in the food prototypes tested, or a confirmed or suspected diagnosis of Celiac Disease.\n* History of severe allergic reactions to any type of allergen.\n* Pregnancy or Breastfeeding","65 Years",{"count":89,"type":23},40,[26],"This study investigates the effects of foods enriched with alternative protein sources, including edible insects, microalgae, hemp, and legumes, on appetite regulation, satiety, food preferences, and metabolic health in healthy adults and individuals with overweight. The study is part of the CIPROMED project, which aims to support sustainable and circular food systems in the Mediterranean area.\n\nThe study consists of two phases. In the acute phase, participants will consume different protein-enriched bread products in a controlled setting following a randomized crossover design. Each participant will be exposed to multiple test conditions, allowing within-subject comparisons of postprandial responses. Outcomes assessed during this phase include satiety, hunger, food preference, craving, and short-term energy intake, measured using validated scales and dietary assessment tools.\n\nIn the chronic phase, participants will follow structured dietary interventions over a longer period within a Mediterranean dietary framework. Participants will be assigned to different dietary patterns including alternative protein-based foods and control products. This phase aims to evaluate the effects of repeated consumption of alternative protein sources on metabolic parameters, gastrointestinal tolerance, nutritional status, and behavioral responses.\n\nThe study aims to assess the acceptability and physiological effects of alternative protein sources and to compare their impact with that of traditional protein sources commonly used in Mediterranean diets.",[93,94,95,30,96],"Food Preferences","Satiety and Food Intake","Appetite Regulation","Gut Microbiota",[98,99,100,101,95,102,103,104,105,106,107,96],"Alternative Proteins","Edible Insects","Hemp Protein","Legume Protein","Overweight","Novel Foods","Microalgae (Protein)","Food Acceptability","Satiety","Metabolic Health","RECRUITING","2026-04-28",{"date":69,"type":44},{"date":112,"type":44},"2026-03-18",{"date":114,"type":23},"2027-01-31",{"name":116,"class":51},"University of Bologna",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":24,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100621562","ssrd-and-overweight-100621562","NCT07372235","SSRD and Overweight","Comparison at Overweight Between Those Who Receive Feedback Concerning Their Metabolic Profile or Not During an Intervention With Modified Starch- and Sucrosereduced Diet (SSRD)","SSRD","Inclusion Criteria:\n\n* Ålder 18-70 år och språkkunskaper i svenska så att de kan tillgodogöra sig kostinformationen och ifylla formulären.\n* BMI ≥25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allvarlig födoämnesallergi\n* Allvarlig hjärt, lung, kardiovaskulär, magtarm, malign eller psykisk sjukdom\n* Pågående ätstörning\n* Graviditet\n* Står redan på en diet såsom vegan diet, regelbunden fasta \\>15 timmar per dag, eller låg kolhydrat hög fett (LCHF) diet de senaste 3 månaderna\n* Alkohol och\u002Feller drogberoende\n* Stora ändringar i kroppsvikt de senaste 3 månaderna (≥3 kg)\n* Står på viktreducerande läkemedel eller läkemedel som typ GLP-1 analoger","70 Years",{"count":127,"type":23},300,[26],"The investigators have previously found that a starch- and sucrosereduced diet (SSRD) has led decreased gastrointestinal symptoms in patients with irritabel bowel syndrome (IBS). At the same time, investigators found that the weight was reduced and the nutrient intake was improved with a more favorable metabolic profile. However, it is a challenge to change lifestyle, and most persons fail to keep on with an improved diet for a long time. Investigators therefore now want to conduct a clinical trial with SSRD in overweight\u002Fobesity for 3 months. Persons with a BMI \\>25 kg\u002Fm2 will be included. To examine whether a feedback about improved metabolic profile enhances the compliance, participants will be randomized to be informed or not about the metabolic profile after the 6-week visit. Investigator´s hypothesis is that information about the improvement in the metabolic profile should increase the motivation and compliance in the patients, and thereby render better effects.",[30],[132,123,38,133],"overweight","feedback on dietary efficiency",{"date":135,"type":44},"2026-04-29",{"date":137,"type":23},"2026-09-01",{"date":139,"type":23},"2032-12-31",{"name":141,"class":51},"Region Skane",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":52},"100632461","impact-immune-and-musculoskeletal-physiological-adaptations-to-combined-exercise-training--nutrition-100632461","NCT07513987","IMPACT: Immune and Musculoskeletal Physiological Adaptations to Combined Exercise Training & Nutrition","Investigating Different Dairy Wholefoods in Combination With Exercise on Inflammation, Immune Cell Function and Musculoskeletal Health in Overweight Adults","Inclusion Criteria:\n\n* Between the ages of 18 and 50 years\n* Overweight BMI (25.0-29.9) kg\u002Fm2\n* 'Overweight' body fat percentage (males: ≤30%; females: ≤42%)\n* Low to moderately physically active (0-2 times\u002Fweek)\n* Habitual low dairy consumption (≤ 1 serving\u002Fday, assessed via baseline food record)\n\nExclusion Criteria:\n\n* Peri- or postmenopausal status (female)\n* Dairy protein allergy or lactose intolerance\n* Use of vitamin D and\u002For calcium supplements\n* Any musculoskeletal, autoimmune, or inflammatory conditions\n* Use of medication related to a chronic condition","50 Years",{"count":151,"type":23},60,[26],"The purpose of this study is to determine whether 12 weeks of exercise training combined with dairy consumption influences inflammation and immune responses in adults with overweight, compared to exercise training alone.",[30,155],"Males and Females","2026-04-04",{"date":158,"type":44},"2026-04-07",{"date":160,"type":23},"2026-05-01",{"date":162,"type":23},"2027-12-31",{"name":164,"class":51},"York University",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":52},"100631198","anti-inflammatory-effects-of-pecan-nut-oil-supplementation-in-adults-with-overweight-a-randomized-controlled-parallel-group-clinical-trial-100631198","NCT07497555","Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial","Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Non-Randomized Controlled Parallel-Group Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Body mass index (BMI) ≥25 and \\\u003C30 kg\u002Fm² (overweight)\n* Willingness to participate and provide written informed consent\n* Ability to comply with study procedures and attend scheduled visits\n* Stable dietary habits and physical activity levels during the study period\n\nExclusion Criteria:\n\n* Diagnosis of chronic diseases such as diabetes mellitus, cardiovascular disease, liver disease, renal disease, or autoimmune disorders\n* Use of anti-inflammatory medications, lipid-lowering drugs, or dietary supplements within the last 3 months\n* Smoking or excessive alcohol consumption\n* Pregnancy or lactation\n* Known allergy or intolerance to nuts or nut-derived products\n* Participation in another clinical trial within the last 3 months\n* Any condition that, in the investigator's opinion, may interfere with study participation or outcomes","55 Years",{"count":174,"type":23},50,[26],"The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are:\n\nDoes pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)? Does pecan nut oil supplementation improve biochemical parameters such as fasting blood glucose and lipid profile? Researchers will compare an experimental group receiving pecan nut oil to a control group with no intervention to determine its effect on inflammation and metabolic parameters.\n\nParticipants will:\n\nConsume 30 g\u002Fday of cold-pressed pecan nut oil under fasting conditions for 8 weeks (experimental group) Maintain their usual diet and physical activity throughout the study Attend two evaluation visits (baseline and Day 60) for blood sample collection and anthropometric measurements Provide dietary information using a 24-hour dietary recall",[30],[179,132,180,181,182],"pecan nut oil","controlled trial","nutraceuticals","chronic low-grade inflammation","2026-03-23",{"date":185,"type":44},"2026-03-27",{"date":187,"type":44},"2025-10-15",{"date":189,"type":23},"2026-07-30",{"name":191,"class":51},"Universidad Autonoma de Nuevo Leon",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":52},"100613889","time-restricted-eating-for-type-2-diabetes-and-metabolic-health-the-tea-time-trial-100613889","NCT07272460","Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial","Time Restricted-eating and Metabolic Health in Patients With Type 2 Diabetes","TEA-TIME","Inclusion Criteria:\n\n* Individuals with previously diagnosed BMI ≥ 25 kg\u002Fm2 and type 2 diabetes within preceding 10 years.\n* Age 18 - 75 years inclusive\n* Stable weight over past 12 weeks (less than 5% change in body weight) (self-reported)\n* Diabetes treatment consisting of lifestyle only or metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitors either as monotherapy or in combination.\n* Ability to read and understand English\n\nExclusion Criteria:\n\n* Current diabetes treatment with insulin, glucagon-like peptide-1 receptor agonists, and\u002For sulfonylureas.\n* Use of any other pharmacological treatment for weight-loss\n* Previous surgical treatment for weight loss such as gastric bypass or gastric band\n* Any history of eating disorder\n* Currently pregnant or lactating\n* Renal dysfunction as evidenced by estimated glomerular filtration rate \\\u003C 25 ml\u002Fmin by CKD-EPI Creatinine Equation\n* New York Heart Association class II-IV heart failure\n* Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \\>2.5X the upper limit of normal\n* Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)\n* Any other factor likely to limit adherence to the study, in the opinion of the investigators\n* Concurrent participation in another research study relevant to diabetes and metabolic health","75 Years",{"count":202,"type":23},112,[26],"Time-restricted eating - where no food is consumed over a period of time - has been shown to promote weight loss and improve cardio-metabolic function. In individuals with type 2 diabetes, it is also been shown to improve glucose control. The investigators propose a randomized controlled trial to determine whether time-restricted eating is an effective therapeutic strategy that can preserve pancreatic beta-cell function and improve glycemic control early in participants with type 2 diabetes.",[206,30],"Type 2 Diabetes",[208,209,210,211],"Randomized controlled trial","Time-restricted eating","Intermittent fasting","Type 2 diabetes","2026-02-09",{"date":214,"type":44},"2026-02-11",{"date":216,"type":44},"2026-02-01",{"date":218,"type":23},"2029-07-31",{"name":220,"class":51},"Mount Sinai Hospital, Canada",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":231,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":52},"100610549","global-overweight-and-obese-globe-patient-registry-development-and-implementation-of-disease-specific-severity-quality-of-life-and-cost-instruments-100610549","NCT07229027","Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.","GLOBE","Inclusion Criteria:\n\n* Patient group\n\n  1. Patient is aged ≥18 years at the time of survey completion.\n  2. Patient has a BMI over 25 (self-reported)\n  3. Patient is willing to participate in all study activities.\n  4. Patient is able to read, write, and converse in English.\n* Healthcare professional participant must meet the following criteria for inclusion in the study:\n\n  1. HCP is aged ≥18 years at the time of survey completion.\n  2. HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25\n  3. HCP is willing to participate in all study activities.\n  4. HCP is able to read, write, and converse in English.\n\n     Exclusion Criteria:\n\nA participant who meets any of the following criteria will be excluded from the study:\n\n1. Participants do not have the cognitive capacity to provide informed consent.\n2. Participants with severe co-morbidity that might affect study participation.",{"count":229,"type":23},500,"60 Months","OBSERVATIONAL","We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.",[30,234],"Obesity & Overweight","2025-11-13",{"date":237,"type":44},"2025-11-14",{"date":239,"type":44},"2025-11-01",{"date":241,"type":23},"2026-08",{"name":243,"class":244},"Medialis Ltd.","INDUSTRY",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":24,"phases":255,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":267,"locationsCount":52},"100600439","phase-2-effect-of-ketone-esters-on-liver-fat-content-and-metabolic-function-100600439","NCT07097506","Effect of Ketone Esters on Liver Fat Content and Metabolic Function","Effect of Ketone Esters on Liver Fat and Metabolic Function in Adolescents With Obesity and MASLD","JV","Inclusion Criteria:\n\n* Age: ≥18 and ≤25 years;\n* BMI 25.0 - 44.9 kg\u002Fm2;\n* Intrahepatic triglyceride content \\>5% assessed by using magnetic resonance imaging-proton density fat fraction (MRI-PDFF).\n\nExclusion Criteria:\n\n* HbA1C ≥6.5%;\n* taking dietary supplements or medications known to affect our study outcomes including corticosteroids and other drugs associated with steatosis (metformin use will be allowable if participants have taken a stable dose for at least 3 months without any gastrointestinal-related symptoms);\n* active eating disorder, any anaphylactic food allergy and\u002For consuming a very-low-carbohydrate (\\\u003C50 g\u002Fday) diet;\n* Fibroscan controlled attenuation parameter (CAP) score \\\u003C240 dB\u002Fm assessed within last 2 months before entering the study;\n* recent (\\\u003C2 months) history of moderate-severe nausea, vomiting, diarrhea, or other significant gastrointestinal symptoms;\n* consume tobacco products, excessive alcohol (females: \\>14 drinks\u002Fweek; males: \\>21 drinks\u002Fweek), or illegal drugs determined by medical history;\n* evidence of significant active organ system dysfunction, liver disease other than MASLD (e.g., Wilson disease, viral hepatitis, inborn errors of metabolism, or alpha-1 antitrypsin deficiency) or cirrhosis as a results of any condition or disease;\n* have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity;\n* have undergone organ transplantation;\n* have HIV and any other type of congenital or acquired lipodystrophy;\n* unwilling or unable to provide informed consent;\n* major psychiatric illness;\n* metal implants that are not MRI-compatible;\n* pregnancy, as determined by a urine HCG screening test assessed performed at all screening, baseline testing, and follow-up visits. In addition, male and female participants of reproductive and childbearing age who wish to enroll will be required to agree to use contraception throughout the study period, and for 30 days after the last dose of C8 ketone di-ester;\n* female participants who are currently lactating;\n* Structured exercise: ≥75 min\u002Fwk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥200 min\u002Fwk of low intensity physical activity (e.g., brisk walking);\n* Unstable weight (\\>3% change during the last 2 months before entering the study);\n* Anemia (hemoglobin \\\u003C10.5 g\u002FdL in females and \\\u003C11.0 g\u002FdL in males);\n* Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.","25 Years",{"count":89,"type":23},[256],"PHASE2","The goal of this clinical trial is to determine whether ingestion of a ketone ester drink helps improve liver health and blood glucose control. Ketones are a type of energy source made by the body during times of weight loss, low carbohydrate intake and starvation.\n\nPeople enrolled in this study will be randomly assigned (by chance, like the flip of a coin) to one of two groups:\n\nGroup 1: Ketone ester drink consumed daily for 6 weeks. Group 2: Placebo drink consumed daily for 6 weeks.",[259,260,30],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Obesity","2025-11-10",{"date":263,"type":44},"2025-11-12",{"date":265,"type":44},"2025-09-26",{"date":162,"type":23},{"name":268,"class":51},"Washington University School of Medicine"]